SCHEMBL4665886

SCHEMBL4665886

COc1ccc(S(=O)(=O)N(OC=O)c2ccc(Nc3cc(-c4ccc(OCCC5CCN(C)CC5)c(F)c4)ncn3)cc2)cc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 5/20 0.37
FGFR1 P11362 2/20 0.37
FLT1 P17948 2/20 0.37
FLT4 P35916 2/20 0.37
KDR P35968 2/20 0.37
IKBKE Q14164 5/20 0.35
TBK1 Q9UHD2 5/20 0.35
BACE1 P56817 1/20 0.35
ABL1 P00519 4/20 0.35
BCR P11274 4/20 0.35
SYK P43405 1/20 0.35
CDK2 P24941 1/20 0.35
MEN1 O00255 2/20 0.34
USP2 O75604 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KMT2A Q03164 2/20 0.34
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
GLA P06280 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4665748 0.93 EGFR (0.42) EGFRFGFR1FLT1FLT4KDR
SCHEMBL4664347 0.93 USP2 (0.40) EGFRFGFR1FLT1FLT4KDR
SCHEMBL4664277 0.90 EGFR (0.43) EGFRFGFR1FLT1FLT4KDR
SCHEMBL4667466 0.90 ABL1 (0.36) EGFRFGFR1FLT1FLT4KDR
SCHEMBL4665785 0.90 EGFR (0.35) EGFRFGFR1FLT1FLT4KDR
SCHEMBL4666156 0.89 EGFR (0.41) EGFRFGFR1FLT1FLT4KDR
SCHEMBL4665896 0.89 MEN1 (0.38) EGFRFGFR1FLT1FLT4KDR
SCHEMBL4663941 0.89 EGFR (0.40) EGFRKDRBACE1ABL1BCR
SCHEMBL4664360 0.88 SYK (0.35) EGFRFGFR1FLT1FLT4KDR
SCHEMBL4665787 0.88 ABL1 (0.41) EGFRKDRABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 EGFR 279/4885FGFR1 170/4885FLT1 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.